CA3061088A1 - Parathyroid hormone fusion polypeptide - Google Patents
Parathyroid hormone fusion polypeptide Download PDFInfo
- Publication number
- CA3061088A1 CA3061088A1 CA3061088A CA3061088A CA3061088A1 CA 3061088 A1 CA3061088 A1 CA 3061088A1 CA 3061088 A CA3061088 A CA 3061088A CA 3061088 A CA3061088 A CA 3061088A CA 3061088 A1 CA3061088 A1 CA 3061088A1
- Authority
- CA
- Canada
- Prior art keywords
- fusion polypeptide
- amino acid
- seq
- acid sequence
- parathyroid hormone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1706781.0A GB201706781D0 (en) | 2017-04-28 | 2017-04-28 | Parathyroid hormone fusion polypeptide |
| GB1706781.0 | 2017-04-28 | ||
| PCT/GB2018/051120 WO2018197895A2 (en) | 2017-04-28 | 2018-04-27 | Parathyroid hormone fusion polypeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3061088A1 true CA3061088A1 (en) | 2018-11-01 |
Family
ID=59011076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3061088A Pending CA3061088A1 (en) | 2017-04-28 | 2018-04-27 | Parathyroid hormone fusion polypeptide |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11344606B2 (https=) |
| EP (1) | EP3609913A2 (https=) |
| JP (2) | JP2020519250A (https=) |
| CN (1) | CN110546159B (https=) |
| CA (1) | CA3061088A1 (https=) |
| GB (1) | GB201706781D0 (https=) |
| WO (1) | WO2018197895A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201706781D0 (en) * | 2017-04-28 | 2017-06-14 | Univ Sheffield | Parathyroid hormone fusion polypeptide |
| SG11202106223RA (en) * | 2019-01-11 | 2021-07-29 | Radius Health Inc | Methods for detecting neutralizing antibodies to parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp) analog |
| CN111876388A (zh) * | 2020-07-24 | 2020-11-03 | 赛瑞诚(苏州)生物科技有限公司 | 一种骨和骨组织靶向外泌体及其制备方法和应用 |
| CN118126197B (zh) * | 2024-03-19 | 2025-02-25 | 康众(广东)生物医药有限公司 | 一种重组pth融合蛋白及其构建方法与应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
| JPH11285388A (ja) | 1998-04-03 | 1999-10-19 | Jcr Pharmaceuticals Co Ltd | キメラレセプター発現細胞とその用途 |
| AU2001257169C1 (en) | 2000-04-21 | 2011-06-16 | Tufts Medical Center, Inc. | G-protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same |
| EP1771467A2 (en) | 2004-07-26 | 2007-04-11 | Asterion Limited | Linkers |
| KR100700869B1 (ko) | 2005-06-03 | 2007-03-29 | 재단법인 목암생명공학연구소 | Pth, 완충제 및 안정제를 포함하는 안정한 pth조성물 |
| WO2008124166A2 (en) | 2007-04-09 | 2008-10-16 | The Board Of Trustees Of The University Of Arkansas | Fusion proteins of collagen-binding domain and parathyroid hormone |
| GB0717985D0 (en) | 2007-07-20 | 2007-10-24 | Asterion Ltd | Growth hormone fusion proteins |
| EP2411038B1 (en) | 2009-03-27 | 2016-12-28 | Van Andel Research Institute | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use |
| CN105153313A (zh) | 2010-02-16 | 2015-12-16 | 诺沃—诺迪斯克有限公司 | 因子viii融合蛋白 |
| WO2011143406A2 (en) | 2010-05-13 | 2011-11-17 | The General Hospital Corporation | Parathyroid hormone analogs and uses thereof |
| GB201104285D0 (en) * | 2011-03-15 | 2011-04-27 | Asterion Ltd | Modified receptor fusion proteins |
| WO2013120060A1 (en) | 2012-02-09 | 2013-08-15 | The Board Of Trustees Of The University Of Arkansas | Delivery of therapeutic agents by a collagen binding protein |
| ES2695161T3 (es) | 2011-12-14 | 2019-01-02 | Univ Arkansas | Administración de agentes terapéuticos mediante una proteína de unión a colágeno |
| WO2013108235A1 (en) | 2012-01-20 | 2013-07-25 | Lupin Limited | Stabilized pth formulation |
| CA2919477A1 (en) * | 2013-07-31 | 2015-02-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules |
| JP6805174B2 (ja) | 2015-05-12 | 2020-12-23 | アメリカ合衆国 | 神経成長因子シグナルペプチド及び副甲状腺ホルモンを含むaav分離株及び融合タンパク質 |
| GB201706781D0 (en) * | 2017-04-28 | 2017-06-14 | Univ Sheffield | Parathyroid hormone fusion polypeptide |
-
2017
- 2017-04-28 GB GBGB1706781.0A patent/GB201706781D0/en not_active Ceased
-
2018
- 2018-04-27 EP EP18782783.7A patent/EP3609913A2/en not_active Withdrawn
- 2018-04-27 CA CA3061088A patent/CA3061088A1/en active Pending
- 2018-04-27 WO PCT/GB2018/051120 patent/WO2018197895A2/en not_active Ceased
- 2018-04-27 CN CN201880027437.0A patent/CN110546159B/zh not_active Expired - Fee Related
- 2018-04-27 JP JP2019558571A patent/JP2020519250A/ja active Pending
- 2018-04-27 US US16/608,611 patent/US11344606B2/en active Active
-
2022
- 2022-03-30 US US17/708,394 patent/US20220218790A1/en not_active Abandoned
- 2022-12-19 JP JP2022202078A patent/JP2023027315A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220218790A1 (en) | 2022-07-14 |
| JP2023027315A (ja) | 2023-03-01 |
| WO2018197895A3 (en) | 2019-01-17 |
| CN110546159B (zh) | 2023-08-22 |
| WO2018197895A2 (en) | 2018-11-01 |
| US20200164033A1 (en) | 2020-05-28 |
| CN110546159A (zh) | 2019-12-06 |
| JP2020519250A (ja) | 2020-07-02 |
| GB201706781D0 (en) | 2017-06-14 |
| US11344606B2 (en) | 2022-05-31 |
| EP3609913A2 (en) | 2020-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220218790A1 (en) | Parathyroid hormone fusion polypeptide | |
| AU2002213843B2 (en) | Apolipoprotein analogues | |
| KR102692516B1 (ko) | 융합 단백질을 포함하는 간염증, 간섬유화 및 간경화 예방 또는 치료용 약학적 조성물 | |
| US20120238496A1 (en) | Fusion protein regulating plasma glucose and lipid, its preparation method and use | |
| US10822386B2 (en) | Insulin analogues with enhanced stability and reduced mitogenicity | |
| US7223726B2 (en) | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same | |
| CN106459222A (zh) | Mic‑1融合蛋白及其用途 | |
| KR20100043201A (ko) | 성장 호르몬 융합 단백질 | |
| WO2015031316A1 (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| CN104968674A (zh) | 具有胆固醇流出活性的新颖的glp-1受体激动剂 | |
| JP2018505874A (ja) | 選択的シグナリング特性及びより低い分裂促進性を有するインスリンアナログ | |
| CN113105561A (zh) | 一种双靶点融合蛋白的制备方法和应用 | |
| JP2018502908A (ja) | アルファ‐1‐ アンチトリプシン(a1at)融合タンパク質及びその使用 | |
| EP2948166B1 (en) | N-terminal truncated insulin analogues | |
| EP0832221A1 (en) | Bone stimulating factor | |
| US20220135640A1 (en) | Cortistatin or an analogue thereof as a pharmaceutically active agent in latent form | |
| AU2008201887B2 (en) | Apolipoprotein analogues | |
| WO2015193378A1 (en) | Novel glp-1 receptor agonists with cholesterol efflux activity | |
| Rand-Weaver et al. | A rapid procedure for the isolation of bioactive growth hormone | |
| RU2792236C1 (ru) | Производное полипептида и способ его получения | |
| EP2768520A1 (en) | Chemically and thermodynamically stable insulin analogues and improved methods for their production | |
| KR20180132833A (ko) | Mcm 결핍과 관련된 장애의 치료를 위한 메틸말로닐 조효소 a 뮤타아제 (mcm) 융합 구조체 | |
| Delgado Mora et al. | Cortistatinor an analogue thereof as a pharmaceutically active agent in latent form | |
| WO2025226713A1 (en) | Compositions and methods for producing active proteins from inactive proproteins | |
| US20030027753A1 (en) | Bone stimulating factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220505 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20241029 |
|
| N11 | Application terminated |
Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE Effective date: 20251029 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251230 |